COMPANY RESEARCHD&D Pharmatech Co., Ltd.
D&D Pharmatech is a South Korea-based biotechnology developer focusing on investigational medicines for metabolic and other serious diseases. Its official site describes GLP-1 peptide-based treatments and oral peptide technologies alongside global clinical development efforts. The Korean Financial Supervisory Service company record identifies the issuer as D&D Pharmatech Inc., KOSDAQ code 347850, with an office in Seongnam. This directory records the listed parent and platform-level focus without attempting to maintain every clinical asset or licensing territory. The company’s official pipeline and investor materials provide up-to-date development information.
Company at a glance
Corporate information
- Company entity
- D&D Pharmatech Inc.（South Korean listed entity）
- Headquarters / principal office
- Seongnam-si, Gyeonggi-doSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters.
Sources (1)
- Company-managed LinkedIn profile — self-reported locationChecked 2026-11-04; source publication date retained where stated
- Founded
- 2014
Sources (1)
- Company HistoryNot stated
- Ownership / capital status
- Publicly tradedPublicly traded
Sources (1)
- D&D Pharmatech发行人信息Not stated
- Official corporate reference
- https://www.ddpharmatech.com/
Sources (1)
- Company HistoryNot stated
- LinkedIn company page
- LinkedIn ↗
Sources (1)
- D&D Pharmatech 公司主页Not stated
- Latest financing / award identified
- 2018-03 · Series A (historical disclosure) · KRW 19 billion
Sources (1)
- Company HistoryNot stated
Historical round; it does not represent the latest financing since the IPO.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
D&D Pharmatech is a South Korea-based biotechnology developer focusing on investigational medicines for metabolic and other serious diseases. Its official site describes GLP-1 peptide-based treatments and oral peptide technologies alongside global clinical development efforts. The Korean Financial Supervisory Service company record identifies the issuer as D&D Pharmatech Inc., KOSDAQ code 347850, with an office in Seongnam. This directory records the listed parent and platform-level focus without attempting to maintain every clinical asset or licensing territory. The company’s official pipeline and investor materials provide up-to-date development information.
KOSDAQ: 347850
peptide-therapeutics · GLP-1 · drug-discovery
metabolic-disease · MASH · obesity
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
ORALINK combines ligand conjugation, lipidation, and excipient strategies. The α4β7 cyclic peptide program with QIC is in lead optimization; its GLP-1 human evidence does not transfer to cyclic peptides.
Business, technology & evidence
- 2026-06-17LG AI Research and D&D Pharmatech partner on oral peptides, including macrocycles
- 2026-08-28D&D Pharmatech and QIC launch supported oral α4β7 peptide discovery program
- D&D Pharmatech is a South Korea-based biotechnology developer focusing on investigational medicines for metabolic and other serious diseases. Its official site describes GLP-1 peptide-based treatments and oral peptide technologies alongside global clinical development efforts. The Korean Financial Supervisory Service company record identifies the issuer as D&D Pharmatech Inc., KOSDAQ code 347850, with an office in Seongnam. This directory records the listed parent and platform-level focus without attempting to maintain every clinical asset or licensing territory. The company’s official pipeline and investor materials provide up-to-date development information.
- SecuritiesKOSDAQ: 347850
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Oral α4β7 cyclic peptide (with QIC) | α4β7 · IBD | 先导优化 | Quantitative human results not confirmed in this review |
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Human oral evidence for the α4β7 cyclic peptide has not been confirmed.
- The GLP-1 program's >5% platform claim cannot be extrapolated to human bioavailability of this cyclic peptide.
- QIC 与 D&D 口服 α4β7 环肽项目 ↗QIC · Undated
- ORALINK 技术机制 ↗D&D Pharmatech · Undated
- D&D 口服 GLP-1 管线 ↗D&D Pharmatech · Undated
- LG AI Research 与 D&D 联合研发 ↗LG AI Research · PR Newswire · 2026-06-17
- D&D Pharmatech and QIC launch supported oral α4β7 peptide discovery program ↗D&D Pharmatech · 2026-08-28
- Official issuer and R&D disclosure · D&D Pharmatech Co., Ltd. ↗D&D Pharmatech Co., Ltd. ·
- Official issuer and R&D disclosure · D&D Pharmatech Co., Ltd. ↗D&D Pharmatech Co., Ltd. ·
- Company History ↗D&D Pharmatech · Not stated
- D&D Pharmatech 公司主页 ↗D&D／LinkedIn · Not stated
- 디앤디파마텍 ↗D&D Pharmatech Inc.（South Korean listed entity） · Accessed 2026-11-04; undated unless stated
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.